

# Chapter 7

## Polycystic Ovary Syndrome PCOS and Depression Role of Neuroinflammation

**Mohammad Reza Ramezanzpour**

*Pediatric Urology and Regenerative Medicine Research Center, Gene, Cell, and Tissue Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran*

**Omid Bahrami**

*Pediatric Urology and Regenerative Medicine Research Center, Gene, Cell, and Tissue Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran*

**Muhammad Parsa Pashazadeh**

*Pediatric Urology and Regenerative Medicine Research Center, Gene, Cell, and Tissue Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran*


**Rojin Sarallah**

*Islamic Azad University Medical Branch of Tehran, Tehran, Iran*

**Reza Nikfar**

*Pediatric Urology and Regenerative Medicine Research Center, Gene, Cell, and Tissue Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran*

**Masoumeh Majidi Zolbin**

 <https://orcid.org/0000-0002-1351-8955>  
*Iranian Tissue Bank and Research Center, Tehran University of Medical Sciences, Tehran, Iran*

DOI: 10.4018/979-8-3693-5908-2.ch007

## ABSTRACT

*Polycystic ovary syndrome (PCOS) is a multidimensional condition with metabolic, hormonal, and neuropsychiatric effects. Depression is common among PCOS patients, and emerging research shows neuroinflammation as a probable reason. Chronic low-grade inflammation, insulin resistance, hyperandrogenism, and gut dysbiosis all contribute to neuroinflammatory processes, which result in hypothalamic dysfunction, neurotransmitter imbalances, and hypothalamic-pituitary-adrenal (HPA) axis dysregulation. Abnormal microglial activation and oxidative stress may further damage neuroplasticity, interfering with proper mood regulation. This chapter investigates how neuroinflammatory pathways influence the relationship between PCOS and depression, focusing on their effects on brain function and mood regulation. This chapter addresses neuroinflammation as a mechanism contributing to psychiatric symptoms in PCOS by identifying key inflammatory drivers, as well as prospective treatment targets.*

## INTRODUCTION

Polycystic Ovary Syndrome (PCOS) is a common condition that affects between 4% and 20% of women during their reproductive years (Deswal et al., 2020). Although genetic factors, particularly genes linked to ovarian and adrenal hormone production, like those in the CYP family, contribute to PCOS, environmental influences also play a major role in how the condition develops and progresses. Environmental toxins, such as endocrine-disrupting chemicals (EDCs) like bisphenol A (BPA) and advanced glycation end-products (AGEs), may aid in the development and exacerbation of PCOS by disrupting hormonal and metabolic balance, especially when exposure occurs during critical developmental periods (Rutkowska & Diamanti-Kandarakis, 2016). When combined with genetic susceptibility, environmental factors can worsen the metabolic and hormonal imbalances commonly seen in PCOS-affected individuals.

The genetic and environmental metabolic impairments underlying PCOS primarily drive the condition through functional ovarian hyperandrogenism, characterized by dysregulated androgen secretion. This dysfunction is associated with the overexpression of steroidogenic enzymes, particularly cytochrome P450c17, in ovarian theca cells. Insulin resistance and obesity deteriorate hyperandrogenism through increasing ovarian sensitivity to luteinizing hormone (LH) (Rosenfield & Ehrmann, 2016). These disruptions cause diverse physical and psychological symptoms.

PCOS symptoms include menstruation abnormalities, weight gain, exhaustion, hirsutism, thinning hair, infertility, acne, mood changes, pelvic discomfort, and sleep difficulties, with depression being one of the most often reported psychological

32 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage: [www.igi-global.com/chapter/polycystic-ovary-syndrome-pcos-and-depression-role-of-neuroinflammation/385877](http://www.igi-global.com/chapter/polycystic-ovary-syndrome-pcos-and-depression-role-of-neuroinflammation/385877)

## Related Content

---

### Play Therapy for Children With Neurodevelopmental Disorders

Gaurav Thapliyaland Sushma Kotnala (2019). *Emerging Trends in the Diagnosis and Intervention of Neurodevelopmental Disorders* (pp. 264-280).

[www.irma-international.org/chapter/play-therapy-for-children-with-neurodevelopmental-disorders/215175](http://www.irma-international.org/chapter/play-therapy-for-children-with-neurodevelopmental-disorders/215175)

### An Overview of Pediatric Neuropsychology

Evangelia Stanitsaand Akyllina Despoti (2025). *Clinical Applications of Pediatric Neuropsychology from Infancy to Adolescence* (pp. 1-22).

[www.irma-international.org/chapter/an-overview-of-pediatric-neuropsychology/376063](http://www.irma-international.org/chapter/an-overview-of-pediatric-neuropsychology/376063)

### Application of Advanced Hearing Aid Technology in Pediatric Hearing Aid Fitting

Prashanth Prabhu (2019). *Emerging Trends in the Diagnosis and Intervention of Neurodevelopmental Disorders* (pp. 76-84).

[www.irma-international.org/chapter/application-of-advanced-hearing-aid-technology-in-pediatric-hearing-aid-fitting/215164](http://www.irma-international.org/chapter/application-of-advanced-hearing-aid-technology-in-pediatric-hearing-aid-fitting/215164)

### Neurodevelopmental Disorders During Early Childhood

(2026). *Neurodevelopmental Disorders in Education: The Clinical Continuum From Childhood to Adulthood* (pp. 85-108).

[www.irma-international.org/chapter/neurodevelopmental-disorders-during-early-childhood/402521](http://www.irma-international.org/chapter/neurodevelopmental-disorders-during-early-childhood/402521)

### Augmentative and Alternative Communication Systems for Children With Cerebral Palsy

Yashomathiand Gayathri Krishnan (2020). *Interdisciplinary Approaches to Altering Neurodevelopmental Disorders* (pp. 63-86).

[www.irma-international.org/chapter/augmentative-and-alternative-communication-systems-for-children-with-cerebral-palsy/254670](http://www.irma-international.org/chapter/augmentative-and-alternative-communication-systems-for-children-with-cerebral-palsy/254670)